TAmiRNA was founded in 2013 as a biopharmaceutical research and development company and as a spin-off company of the University of Natural Resources and Life Sciences, Vienna, to promote the discovery and development of microRNAs (miRNAs) substantially as tools for diagnosis and treatment of age-related diseases such as osteoporosis, cardiovascular and neurodegenerative diseases. The aim of the research work is to advance early risk assessment of age-associated diseases, and thus to give physicians a tool for timely initiation of counteractive measures. This should result in increasing the quality of life for older patients and people. Furthermore, tests for personalized medicine will be developed to support the choice of the best treatment options for patients and also may reflect the therapeutic success. Publications
Co-Founder and CEO: Matthias Hackl, PhD
Co-Founder and CFO: Otto Kanzler
Co-Founder and Scientific Advisor: Regina Grillari, PhD assoc Prof.
Please click here for TAmiRNA's products.